Benzinga · Sep 28, 2026
Lite Strategy Q4 EPS $(0.38) Up From $(0.40) YoY
Lite Strategy (NASDAQ:LITS) reported quarterly losses of $(0.38) per share. This is a 5 percent increase over losses of $(0.40) per share from the same period last year.
LI
NASDAQ · LITS
Lite Strategy, Inc.
Healthcare · Biotechnology
$1.41
Down-$0.12 (-8.16%)
Updated Oct 7, 2026, 4:13 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 66.58M
- P/E ratio
- -4.61
- Dividend yield
- 0.00%
- 52-week range
- $0.69 – $1.54
- Volume
- 493.96K
- Avg. volume
- 780.81K
Price performance · LITS
LITS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
LITS closed at $1.41 after 21 trading sessions, up 28.18% for the selected period.
- Last close
- $1.41
- Period change
- +28.18%
- Period low
- $1.02
- Period high
- $1.44
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.40 | $1.44 | $1.37 | $1.41 | 493.96K |
| Oct 5, 2026 | $1.40 | $1.43 | $1.36 | $1.40 | 435.15K |
| Oct 2, 2026 | $1.47 | $1.50 | $1.37 | $1.38 | 1.01M |
| Oct 1, 2026 | $1.31 | $1.41 | $1.28 | $1.375 | 1.04M |
| Sep 30, 2026 | $1.38 | $1.395 | $1.315 | $1.32 | 331.26K |
| Sep 29, 2026 | $1.35 | $1.41 | $1.34 | $1.375 | 627.83K |
| Sep 28, 2026 | $1.40 | $1.46 | $1.32 | $1.36 | 952.09K |
| Sep 25, 2026 | $1.43 | $1.53 | $1.365 | $1.44 | 2.27M |
| Sep 24, 2026 | $1.33 | $1.54 | $1.31 | $1.43 | 5.37M |
| Sep 23, 2026 | $1.28 | $1.31 | $1.17 | $1.18 | 585K |
| Sep 22, 2026 | $1.26 | $1.315 | $1.24 | $1.30 | 610.75K |
| Sep 21, 2026 | $1.20 | $1.3287 | $1.08 | $1.28 | 1.61M |
| Sep 18, 2026 | $1.07 | $1.15 | $1.03 | $1.13 | 1.04M |
| Sep 17, 2026 | $1.065 | $1.13 | $1.04 | $1.04 | 904.98K |
| Sep 16, 2026 | $1.07 | $1.07 | $0.9949 | $1.02 | 318.76K |
| Sep 15, 2026 | $1.14 | $1.169 | $1.05 | $1.09 | 318.73K |
| Sep 14, 2026 | $1.11 | $1.195 | $1.11 | $1.15 | 329.74K |
| Sep 11, 2026 | $1.06 | $1.1193 | $1.06 | $1.11 | 278.1K |
| Sep 10, 2026 | $1.00 | $1.10 | $1.00 | $1.06 | 230.96K |
| Sep 9, 2026 | $1.11 | $1.13 | $1.032 | $1.06 | 488.36K |
| Sep 8, 2026 | $1.14 | $1.151 | $1.09 | $1.10 | 286.75K |
Latest LITS news
The latest Smart Investors Daily articles mentioning LITS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LITS research
Overview
Company profile and research snapshot.
Company profile
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Lite Strategy Files Prospectus For Offering 1.889M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1262104/000119312526405423/lits-20260928.htm
Benzinga · Jul 30, 2026
Lite Strategy Says It Funded $5.4M Buyback Through Litecoin Sales And Covered Call Premiums; Holds 819,070 LTC Against 31,882,648 Shares Outstanding
Benzinga · Feb 17, 2026
Lite Strategy Q2 EPS $(0.82) Down From $(0.40) YoY
Lite Strategy (NASDAQ:LITS) reported quarterly losses of $(0.82) per share. This is a 105 percent decrease over losses of $(0.40) per share from the same period last year.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
